Equities

Lucy Scientific Discovery Inc

LSDI:NAQ

Lucy Scientific Discovery Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.59
  • Today's Change0.00 / 0.00%
  • Shares traded2.18m
  • 1 Year change-82.81%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.

  • Revenue in USD (TTM)16.73k
  • Net income in USD-9.76m
  • Incorporated2017
  • Employees--
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
LSDI:NAQ since
announced
Transaction
value
Bluesky Wellness IncDeal completed12 Sep 202312 Sep 2023Deal completed117.81%--
Pasithea Therapeutics CorpDeal withdrawn06 Jun 202306 Jun 2023Deal withdrawn-85.93%22.21m
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
DSwiss Inc1.47m-49.54k2.59m11.00--45.84157.511.76-0.0002-0.00020.00710.00033.92154.8254.81133,643.60-13.22-8.69-50.26-45.4724.4425.55-3.37-2.471.05-15.740.3961---20.5046.20-688.36---66.17--
AgriFORCE Growing Systems Ltd16.28k-11.73m2.60m7.00--0.0784--159.46-14.14-14.140.0141.470.0008--0.4082,325.71-59.84-78.95-84.37-109.8616.58---72,071.25-243,182.500.6922-1.390.3253------8.85--48.61--
Eloxx Pharmaceuticals Inc0.00-20.48m2.63m18.00---------9.06-9.060.00-6.530.00----0.00-124.43-115.27---155.33-----------16.69--------45.95---22.56--
Applied DNA Sciences Inc5.52m-12.50m2.71m53.00------0.4908-17.13-17.137.67-0.05580.389310.384.64104,110.80-87.15-88.57-111.09-121.9133.9844.35-223.89-113.261.54-------26.4327.92-18.73--33.80--
Agile Therapeutics Inc21.50m-7.79m2.74m19.00------0.1274-3.65-3.656.98-1.511.632.905.421,131,316.00-59.25-94.24---142.6259.73---36.26-513.500.3843------80.02--43.08------
Aridis Pharmaceuticals Inc22.36m-1.14m2.76m37.00------0.1236-0.1845-0.18450.7074-0.26482.40--58.45604,297.30-12.24-120.16---678.29-----5.11-1,559.63--------101.3729.1634.43---34.84--
Avenue Therapeutics Inc0.00-7.18m2.79m3.00--0.7554-----39.36-39.360.004.810.00----0.00-123.08-186.91-1,045.52-287.70------------0.00-------192.15------
Lucy Scientific Discovery Inc16.73k-9.76m2.81m----34.57--167.72-6.34-7.210.01030.0460.0037--0.7276---215.45------49.97---58,360.55-----5.100.4615-------53.49------
Novelstem International Corp12.00k-4.19m2.81m15.00------234.41-0.0893-0.08930.0003-0.04160.0053--2.00---171.11---188.15-------32,373.50-----9.822.20--0.00---446.84------
Mosaic Immunoengineering Inc0.00-1.01m2.82m3.00---------0.1397-0.13970.00-0.81070.00----0.00-457.45-----------------35.84--------57.65------
Regen BioPharma Inc236.58k-851.69k2.86m1.00------12.09-0.2271-0.22710.0633-1.260.8644--3.98236,580.00-327.54-104.36---------378.93-275.00---1.32----0.441618.79-58.11------
Axim Biotechnologies Inc39.77k-8.06m2.91m6.00------73.29-0.0366-0.03660.0001-0.03110.0095----6,628.33-193.43-154.34---390.73-----20,265.75-36,362.71---0.62----345.05-27.38-29.10------
Veritas Farms Inc730.65k-6.15m2.95m17.00--14.57--4.04-0.1319-0.13190.01360.00130.08770.80647.8042,979.41-69.02-72.11-123.21-93.59-220.0924.07-787.27-177.790.1392-5.560.95---63.42-0.942723.68---52.93--
Navidea Biopharmaceuticals Inc610.00-8.81m3.00m11.00------4,922.18-0.2086-0.05470.00001-0.03270.00010.15290.006655.45-143.97-169.68---753.52-8,103.2891.34-1,411,062.00-1,938.530.5066-------87.65-48.49-46.75--63.23--
Biostax Corp0.00-1.65m3.01m-----------0.0198-0.01980.00-0.04560.00-------193.36-75.14---------------8.97--------53.32------
Data as of May 17 2024. Currency figures normalised to Lucy Scientific Discovery Inc's reporting currency: US Dollar USD

Institutional shareholders

7.14%Per cent of shares held by top holders
HolderShares% Held
AdvisorShares Investments LLCas of 31 Dec 202388.23k5.00%
K2 & Associates Investment Management, Inc.as of 31 Dec 202325.00k1.42%
Renaissance Technologies LLCas of 31 Dec 20236.79k0.39%
Citadel Securities LLCas of 31 Dec 20234.29k0.24%
HRT Financial LLCas of 31 Dec 20231.74k0.10%
Walleye Capital LLCas of 31 Dec 20230.000.00%
JPMorgan Securities LLC (Investment Management)as of 31 Mar 20240.000.00%
Sageworth Trust Co.as of 31 Mar 20240.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.